Peptides are among the most actively researched compounds in dermatology and cosmetic science. From copper-binding tripeptides that stimulate collagen synthesis to anti-inflammatory fragments that calm chronic skin conditions, peptides offer a range of mechanisms for improving skin health. This guide evaluates the peptides with the strongest evidence for skin benefits, comparing their mechanisms, delivery methods, and safety profiles.
The distinction between topical and systemic peptide use matters. Topical peptide skincare products act primarily on the epidermis and upper dermis, while injectable peptides achieve systemic distribution and can influence skin biology from within. Both approaches have trade-offs in efficacy, accessibility, and risk, which are covered in detail below.
How Peptides Improve Skin
Peptides influence skin health through several distinct biological pathways. Understanding these mechanisms helps clarify why different peptides are suited to different skin concerns.
Collagen and elastin synthesis. Peptides such as GHK-Cu directly stimulate fibroblasts to produce collagen types I and III, elastin, and glycosaminoglycans. These structural proteins provide the tensile strength and elasticity that decline with age. Collagen production drops roughly 1% per year after age 30, and peptides that counteract this decline are central to anti-aging skincare.
Growth factor signaling. Some peptides stimulate the release of growth factors, including transforming growth factor beta (TGF-beta), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF), that coordinate tissue repair, angiogenesis, and cell proliferation. BPC-157 and growth hormone-releasing peptides both operate partly through this pathway.
Inflammation modulation. Chronic low-grade inflammation accelerates skin aging (a process termed "inflammaging") and drives conditions such as eczema, psoriasis, and rosacea. Peptides like KPV suppress the NF-kB inflammatory pathway and reduce pro-inflammatory cytokines, addressing the root cause of inflammatory skin damage rather than merely masking symptoms.
Melanocortin signaling. Melanocortin receptor agonists such as Melanotan II stimulate melanogenesis, increasing skin pigmentation. While this pathway has theoretical photoprotective implications, the clinical risk profile of these compounds is significant.
1. GHK-Cu, Best Overall for Skin Rejuvenation
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is the most extensively studied peptide for skin health. Originally isolated from human plasma by Pickart in the 1970s, it occurs naturally in the body and declines with age. Circulating levels drop from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60.
Mechanism. GHK-Cu stimulates collagen synthesis, increases elastin production, promotes glycosaminoglycan accumulation, and supports dermal fibroblast function. Genomic studies have identified its influence on over 4,000 human genes, including those involved in collagen remodeling, antioxidant defense, and DNA repair.
Evidence. A 12-week clinical study of 71 women with mild to advanced photoaging found that a GHK-Cu facial cream improved skin laxity, clarity, and appearance while reducing fine lines and wrinkle depth and increasing skin density and thickness. A separate IRB-approved trial of 21 women showed an average 28% increase in collagen density after 3 months of daily topical application, with the top quartile achieving a 51% increase. In comparative testing, GHK-Cu cream increased collagen production in 70% of subjects over one month, outperforming vitamin C cream (50%) and retinoic acid (40%).
Delivery. GHK-Cu is one of the few peptides with strong evidence for topical efficacy. Its small size (tripeptide, ~403 Da) allows reasonable skin penetration, and copper binding enhances its stability in formulation. It is available in both topical creams and injectable forms.
Best for: Fine lines and wrinkles, overall skin rejuvenation, post-procedure healing, skin thinning.
2. BPC-157, Best for Wound Healing and Skin Repair
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protein in human gastric juice. While it is best known for musculoskeletal and gut healing, its wound repair mechanisms are directly relevant to skin.
Mechanism. BPC-157 promotes angiogenesis (new blood vessel formation), accelerates granulation tissue formation, stimulates collagen deposition, and enhances reepithelialization. It modulates the nitric oxide system and upregulates growth factor receptors, coordinating the complex cascade of wound repair.
Evidence. Animal studies have consistently demonstrated accelerated wound healing with BPC-157 across multiple injury models. In burn wound studies, BPC-157-treated rats showed significantly faster wound closure than controls, with the effect becoming statistically significant by days 12 to 16. Treated groups showed superior granulation tissue formation, reepithelialization, and dermal remodeling. In alkali-burn models, BPC-157 enhanced wound healing both in vivo and promoted fibroblast proliferation, migration, and angiogenesis in vitro.
Limitations. BPC-157 has not completed human clinical trials for wound healing. Previous clinical trials in humans focused on inflammatory bowel disease and multiple sclerosis, with no reported toxicity, but the absence of controlled human skin studies limits the strength of current evidence.
Delivery. For skin applications, BPC-157 has been studied both systemically (subcutaneous injection) and topically (cream formulations applied directly to wounds). Topical application showed efficacy in burn wound models.
Best for: Wound healing, surgical recovery, burn injuries, skin repair after trauma.
3. KPV, Best for Inflammatory Skin Conditions
KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains the potent anti-inflammatory properties of the parent hormone while lacking its pigmentation-altering effects.
Mechanism. KPV suppresses the NF-kB inflammatory signaling pathway and reduces the production of pro-inflammatory cytokines including TNF-alpha and IL-6. It enters cells and directly interacts with inflammatory signaling cascades, making it effective at low concentrations.
Evidence. Preclinical studies have shown that KPV, applied either intravenously or topically, suppressed contact dermatitis reactions and induced hapten-specific immune tolerance. Alpha-MSH applied topically in a cream reduced nickel-induced contact eczema in human subjects. A 2025 study demonstrated that KPV treatment restored cell viability and reduced IL-1beta secretion in human keratinocytes exposed to particulate matter, suggesting protective effects against environmental inflammatory damage.
Safety profile. Unlike corticosteroids, KPV does not appear to suppress broader immune function, increase infection risk, or cause the tissue thinning associated with long-term steroid use. However, it is not approved by the FDA or EMA and remains classified as a research compound.
Delivery. KPV has been studied via intravenous, subcutaneous, oral, and topical routes. Research on transdermal iontophoretic delivery across microporated skin has explored enhanced topical delivery methods. Its small size (tripeptide) is favorable for skin penetration.
Best for: Eczema, contact dermatitis, psoriasis, inflammatory skin conditions, environmentally stressed skin.
4. Melanotan II, Skin Pigmentation
Safety warning: Melanotan II carries serious documented safety risks including published melanoma case reports and formal regulatory warnings from the Australian TGA and UK MHRA. It is not approved by any regulatory agency and should not be considered a recommended option for skin health.
Melanotan II is a synthetic analog of alpha-MSH developed at the University of Arizona in the 1980s. It binds nonselectively to melanocortin receptors, stimulating melanogenesis and increasing skin pigmentation without UV exposure.
Mechanism. By activating MC1R receptors on melanocytes, Melanotan II increases eumelanin production, darkening the skin. It was originally investigated as a potential photoprotective agent to reduce UV-induced skin cancer risk.
Safety concerns. Melanotan II is not approved by the FDA, TGA, EMA, or any major regulatory agency. Its safety profile carries serious red flags:
- Melanoma risk. Multiple case reports document melanoma development in Melanotan II users, and a 2025 review concluded that its use could lead to the development of skin cancer.
- Systemic toxicity. Reports include rhabdomyolysis, renal dysfunction, and sympathomimetic symptoms.
- Nonselective binding. Because Melanotan II activates multiple melanocortin receptor subtypes, it produces widespread off-target effects including nausea, facial flushing, and changes in appetite and sexual function.
- No long-term data. No controlled studies have evaluated the long-term consequences of Melanotan II use.
- Product quality. As an unregulated compound, there is no guarantee of purity, sterility, or accurate dosing in available products.
Given these risks, Melanotan II is included here for completeness but cannot be recommended. The Australian TGA, UK MHRA, and FDA have all issued warnings against its use.
5. GH Peptides (Sermorelin, CJC-1295), Indirect Skin Benefits via Growth Hormone
Growth hormone-releasing peptides do not act directly on skin cells. Instead, they stimulate pituitary growth hormone (GH) release, which in turn elevates insulin-like growth factor 1 (IGF-1) levels. GH and IGF-1 influence skin biology through downstream collagen and elastin synthesis.
Evidence for GH and skin. The landmark 1990 Rudman study in the New England Journal of Medicine found that 6 months of recombinant human GH administration in men over 60 increased skin thickness by 7.1%. Note that Rudman studied recombinant human growth hormone directly, a different pharmacological intervention with a different pharmacokinetic profile from CJC-1295 or other GH-releasing peptides. Extrapolating Rudman's results to CJC-1295 is scientifically imprecise, as the two approaches differ in mechanism, dosing kinetics, and magnitude of GH elevation. A randomized, double-blind, placebo-controlled study of GH-deficient patients confirmed that GH substitution increased collagen type I synthesis (measured by PICP) and skin thickness over 12 months.
Sermorelin is a 29-amino-acid analog of growth hormone-releasing hormone (GHRH) that stimulates physiological GH release. CJC-1295 is a modified GHRH analog with a longer half-life, producing sustained GH and IGF-1 elevations. A clinical study showed that CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults.
Practical considerations. GH peptides require subcutaneous injection and produce systemic rather than targeted skin effects. Benefits to skin are secondary to their primary use for body composition, recovery, and anti-aging. The skin improvements are real but take months to manifest and are accompanied by the full systemic effects of elevated GH, which require medical monitoring.
Best for: Individuals already using GH peptides for other purposes who seek secondary skin thickness and collagen benefits.
Topical vs Injectable Peptides for Skin
The choice between topical and injectable delivery significantly affects what peptides can achieve for skin health.
Topical peptides face a fundamental challenge: the stratum corneum is designed to keep molecules out. Most peptides are hydrophilic with molecular weights that limit passive diffusion through the skin barrier. However, smaller peptides, particularly tripeptides like GHK-Cu and KPV, achieve clinically meaningful penetration. Advanced delivery technologies are improving topical efficacy: nanoliposome-encapsulated peptides demonstrated 25% greater wrinkle volume reduction and 37% greater elasticity improvement compared to free peptides in one study. Similarly, the frequently cited GHK-Cu figures of 55.8% wrinkle volume reduction and 32.8% depth reduction were achieved using nano-carrier/nanoliposome delivery systems; standard topical GHK-Cu formulations may not replicate these results. Lipid conjugation, microneedling, and iontophoresis are additional strategies that enhance peptide delivery through the skin barrier.
Injectable peptides bypass absorption barriers entirely and achieve systemic distribution. This makes them more potent for deep dermal remodeling and systemic effects on skin biology (such as GH-mediated collagen synthesis). However, injectables carry greater risk, require sterile technique, and need medical supervision. They are not appropriate for cosmetic-only skin goals in most cases.
For most people seeking skin health benefits, topical peptides from reputable formulations represent the most practical starting point. Injectable peptides are better suited to clinical settings or individuals with specific therapeutic goals.
What to Look for in Peptide Skincare Products
The peptide skincare market ranges from rigorously formulated clinical products to ineffective marketing vehicles. Several factors separate products that work from those that do not.
Concentration matters. Many products list peptides on their label but contain concentrations too low to produce biological effects. Clinical studies typically use GHK-Cu at concentrations of 0.01% to 1%. Products that do not disclose peptide concentration should be viewed skeptically.
Formulation and stability. Peptides can degrade through oxidation, hydrolysis, and aggregation. Effective formulations use stabilizing agents, appropriate pH buffering, and packaging that minimizes light and air exposure. Airless pump containers are preferable to open jars.
Delivery technology. Products using liposomal encapsulation, nanoparticle delivery, or penetration-enhancing bases will outperform simple aqueous formulations. Look for formulations that specifically address penetration enhancement.
Third-party testing. Certificates of analysis from independent laboratories verify that the product contains what it claims. This is particularly important in a market where regulatory oversight of cosmetic peptide products is limited.
Realistic claims. Products claiming to eliminate wrinkles overnight or replace surgical procedures are misleading. Peptides produce measurable but incremental improvements over weeks to months of consistent use.
Safety Considerations
Topical peptides have a strong overall safety profile. Allergic reactions are uncommon, and systemic absorption from topical application is generally minimal. GHK-Cu in particular has no reported significant adverse effects in clinical studies of topical use.
Injectable peptides carry the standard risks associated with subcutaneous injection, infection, injection site reactions, and potential for contamination in non-pharmaceutical-grade products. GH-releasing peptides have additional considerations including effects on glucose metabolism, potential for joint pain or fluid retention, and theoretical concerns about promoting growth of existing malignancies.
Melanotan II presents a distinct risk category, as outlined above, and should be avoided.
All research peptides exist outside standard pharmaceutical regulation. They are sold for research purposes only, and using them for self-treatment involves accepting risks associated with unregulated products, including potential contamination, inaccurate dosing, and absence of clinical oversight.
Anyone considering peptide use beyond over-the-counter topical skincare should consult a physician experienced in peptide therapy, obtain baseline blood work, and source products only from suppliers that provide third-party certificates of analysis.
Conclusion
Peptides offer a scientifically grounded approach to skin health, with mechanisms spanning collagen synthesis, wound repair, inflammation control, and cellular aging. GHK-Cu stands out as the best-supported option for general skin rejuvenation, with clinical evidence for wrinkle reduction, collagen stimulation, and skin thickness improvement. BPC-157 shows strong preclinical promise for wound healing, KPV offers a novel approach to inflammatory skin conditions, and GH peptides provide indirect skin benefits through systemic growth hormone elevation. For those also interested in longer-term anti-aging outcomes, the best peptides for anti-aging guide examines how these compounds address the underlying hallmarks of biological aging. To understand how GHK-Cu compares to BPC-157 across different goals, see the GHK-Cu vs BPC-157 comparison.
The field is advancing rapidly, with improved delivery technologies making topical peptides more effective and new clinical trials expanding the evidence base. For now, the strongest practical advice is to focus on well-formulated topical GHK-Cu products for general anti-aging, to treat peptide skincare claims with appropriate skepticism, and to reserve injectable peptides for situations where medical supervision and specific therapeutic goals justify their use.